Despite the appreciation in Hologic's HOLX share price YTD, JP Morgan thinks that Hologic remains poised for additional upside based on several factors, including: ample early- adopter demand for Selenia Dimensions tomosynthesis, driving near-term results; and a continued rebound in physician office visits, as noted by JPM's physician survey.
Legitimate longer-term concerns/risks are unlikely to manifest this fiscal year; and accordingly, any change to estimates for 2011 is likely to the upside, in our view. While shares are no longer downright cheap at ~10.6x 2011E EV/EBITDA, JPM continues to believe that risk/reward remains favorable at current levels, as it increase estimates and Dec. 2011 PT from $21 to $24.
HOLX shares have increased 15% YTD and 40% since the September tomosynthesis FDA panel, as improved investor sentiment has driven multiple expansion from <7.0x forward EV/EBITDA to 10.6x today. Despite the appreciation, shares still trade at a discount to the peer group average of 11.3x, though valuation has clearly gone from “downright cheap” to more reasonable.
JP Morgan has a $24 PT and Overweight rating on HOLX
HOLX closed Monday at $21.65
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in